Julio C Fernandes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4257703/publications.pdf

Version: 2024-02-01

78 papers

5,737 citations

34 h-index 75 g-index

80 all docs 80 docs citations

80 times ranked 6964 citing authors

#	Article	IF	CITATIONS
1	The role of cytokines in osteoarthritis pathophysiology. Biorheology, 2002, 39, 237-46.	1.2	713
2	Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 1-8.	2.0	486
3	Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials, 2006, 27, 2060-2065.	5.7	374
4	Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials, 2003, 24, 1255-1264.	5.7	351
5	Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis and Rheumatism, 1996, 39, 1535-1544.	6.7	338
6	Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis and Rheumatism, 1998, 41, 1275-1286.	6.7	318
7	Uptake mechanisms of non-viral gene delivery. Journal of Controlled Release, 2012, 158, 371-378.	4.8	254
8	In Vivo Transfer of Interleukin-1 Receptor Antagonist Gene in Osteoarthritic Rabbit Knee Joints. American Journal of Pathology, 1999, 154, 1159-1169.	1.9	218
9	Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis and Rheumatism, 2000, 43, 1290-1299.	6.7	217
10	Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation. Cell Death and Disease, 2013, 4, e832-e832.	2.7	139
11	Prognostic Factors for Predicting Outcomes After Intramedullary Nailing of the Tibia. Journal of Bone and Joint Surgery - Series A, 2012, 94, 1786-1793.	1.4	115
12	Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. Journal of Cellular Biochemistry, 2011, 112, 107-117.	1.2	113
13	In vivo selective inhibition of mitogen-activated protein kinase kinase $1/2$ in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis and Rheumatism, 2003, 48, 1582-1593.	6.7	112
14	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis. Arthritis and Rheumatism, 2001, 44, 2320-2330.	6.7	100
15	Polycation-Based Gene Therapy: Current Knowledge and New Perspectives. Current Gene Therapy, 2011, 11, 288-306.	0.9	96
16	Synthetic and Natural Polycations for Gene Therapy: State of the Art and New Perspectives. Current Gene Therapy, 2006, 6, 59-71.	0.9	92
17	Bone-protective Effects of Nonviral Gene Therapy With Folate–Chitosan DNA Nanoparticle Containing Interleukin-1 Receptor Antagonist Gene in Rats With Adjuvant-induced Arthritis. Molecular Therapy, 2008, 16, 1243-1251.	3.7	88
18	Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials, 2005, 26, 961-970.	5.7	85

#	Article	IF	CITATIONS
19	Validation of an advanced practice physiotherapy model of care in an orthopaedic outpatient clinic. BMC Musculoskeletal Disorders, 2013, 14, 162.	0.8	84
20	4-Hydroxynonenal induces apoptosis in human osteoarthritic chondrocytes: the protective role of glutathione-S-transferase. Arthritis Research and Therapy, 2008, 10, R107.	1.6	82
21	Production of lipid peroxidation products in osteoarthritic tissues: New evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis and Rheumatism, 2006, 54, 271-281.	6.7	75
22	Synthesis and Characterization of Phosphorylcholine-Substituted Chitosans Soluble in Physiological pH Conditions. Biomacromolecules, 2006, 7, 3151-3156.	2.6	70
23	Trabecular Metal Used for Major Bone Loss in Acetabular Hip Revision. Journal of Arthroplasty, 2011, 26, 1245-1250.	1.5	68
24	Effects of tenidap on canine experimental osteoarthritis i. morphologic and metalloprotease analysis. Arthritis and Rheumatism, 1995, 38, 1290-1303.	6.7	58
25	The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis. Inflammation Research, 2016, 65, 635-645.	1.6	53
26	Differential regulation of cyclooxygenase-2 and inducible nitric oxide synthase by 4-hydroxynonenal in human osteoarthritic chondrocytes through ATF-2/CREB-1 transactivation and concomitant inhibition of NF- \hat{I}^{p} B signaling cascade. Journal of Cellular Biochemistry, 2007, 100, 1217-1231.	1.2	52
27	Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies. International Journal of Nanomedicine, 2012, 7, 5833.	3.3	50
28	Alterations of metabolic activity in human osteoarthritic osteoblasts by lipid peroxidation end product 4-hydroxynonenal. Arthritis Research and Therapy, 2006, 8, R159.	1.6	49
29	Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes. Inflammation Research, 2014, 63, 691-701.	1.6	47
30	Inhibition of inducible nitric oxide synthase prevents lipid peroxidation in osteoarthritic chondrocytes. Journal of Cellular Biochemistry, 2012, 113, 2256-2267.	1.2	45
31	Elucidating the Role of Protandim and 6â€Gingerol in Protection Against Osteoarthritis. Journal of Cellular Biochemistry, 2017, 118, 1003-1013.	1.2	43
32	Progress and Prospects of Chitosan and Its Derivatives as Non-Viral Gene Vectors in Gene Therapy. Current Gene Therapy, 2009, 9, 495-502.	0.9	39
33	In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. Arthritis Research and Therapy, 2019, 21, 72.	1.6	39
34	Expression of ICAM-1 by osteoblasts in healthy individuals and in patients suffering from osteoarthritis and osteoporosis. Bone, 2004, 35, 463-470.	1.4	37
35	Endothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production. Arthritis Research, 2005, 7, R324.	2.0	32
36	Perturbation of adhesion molecule-mediated chondrocyte-matrix interactions by 4-hydroxynonenal binding: implication in osteoarthritis pathogenesis. Arthritis Research and Therapy, 2010, 12, R201.	1.6	32

#	Article	IF	CITATIONS
37	An overview of the role of lipid peroxidation-derived 4-hydroxynonenal in osteoarthritis. Inflammation Research, 2017, 66, 637-651.	1.6	32
38	Fluid Lavage of Open Wounds (FLOW): A Multicenter, Blinded, Factorial Pilot Trial Comparing Alternative Irrigating Solutions and Pressures in Patients With Open Fractures. Journal of Trauma, 2011, 71, 596-606.	2.3	31
39	Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, R223.	1.6	29
40	Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis and Rheumatism, 1997, 40, 284-294.	6.7	28
41	Diethylaminoethyl- chitosan as an efficient carrier for siRNA delivery: Improving the condensation process and the nanoparticles properties. International Journal of Biological Macromolecules, 2018, 119, 186-197.	3.6	27
42	Pluronic F-127 as a Cell Carrier for Bone Tissue Engineering. Journal of Biomaterials Applications, 2009, 24, 275-287.	1.2	24
43	Linear polyethylenimine produced by partial acid hydrolysis of poly(2-ethyl-2-oxazoline) for DNA and siRNA delivery in vitro. International Journal of Nanomedicine, 2013, 8, 4091.	3.3	23
44	Simulation of acoustic guided wave propagation in cortical bone using a semi-analytical finite element method. Journal of the Acoustical Society of America, 2017, 141, 2538-2547.	0.5	21
45	New Evidence Implicating 4â€Hydroxynonenal in the Pathogenesis of Osteoarthritis In Vivo. Arthritis and Rheumatology, 2014, 66, 2461-2471.	2.9	20
46	Involvement of ICAM-1 in bone metabolism: a potential target in the treatment of bone diseases?. Expert Opinion on Biological Therapy, 2005, 5, 313-320.	1.4	18
47	Hydrodynamic Delivery of Chitosan-Folate-DNA Nanoparticles in Rats with Adjuvant-Induced Arthritis. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	18
48	Gene Therapy for Osteoarthritis. Clinical Orthopaedics and Related Research, 2000, 379, S262-S272.	0.7	17
49	<p>Evidence Supporting the Safety of Pegylated Diethylaminoethyl-Chitosan Polymer as a Nanovector for Gene Therapy Applications</p> . International Journal of Nanomedicine, 2020, Volume 15, 6183-6200.	3.3	17
50	Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT). Value in Health, 2011, 14, 450-457.	0.1	16
51	Nuclear receptor retinoid-related orphan receptor $\hat{l}\pm 1$ modulates the metabolic activity of human osteoblasts. Journal of Cellular Biochemistry, 2011, 112, 2160-2169.	1.2	16
52	Treatment of Prosthetic Joint Infections: Validation of a Surgical Algorithm and Proposal of a Simplified Alternative. Journal of Arthroplasty, 2013, 28, 395-400.	1.5	16
53	Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporosis International, 2009, 20, 1571-1581.	1.3	15
54	Polyethylenimine600-& amp; beta; -cyclodextrin: a promising nanopolymer for nonviral gene delivery of primary mesenchymal stem cells. International Journal of Nanomedicine, 2013, 8, 1935.	3.3	15

#	Article	IF	Citations
55	Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study. Archives of Osteoporosis, 2019, 14, 87.	1.0	15
56	Chitosan-Based Nanogels: Synthesis and Toxicity Profile for Drug Delivery to Articular Joints. Nanomaterials, 2022, 12, 1337.	1.9	15
57	siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis. Expert Opinion on Biological Therapy, 2011, 11, 5-16.	1.4	14
58	Efficient Nonviral Gene Therapy Using Folate-Targeted Chitosan-DNA Nanoparticles In Vitro. ISRN Pharmaceutics, 2012, 2012, 1-9.	1.0	14
59	Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. Vascular Health and Risk Management, 2018, Volume 14, 81-89.	1.0	13
60	Performance of a Fracture Liaison Service in an Orthopaedic Setting. Journal of Bone and Joint Surgery - Series A, 2020, 102, 486-494.	1.4	12
61	The pathophysiology of immunoporosis: innovative therapeutic targets. Inflammation Research, 2021, 70, 859-875.	1.6	12
62	An active role for soluble and membrane intercellular adhesion molecule-1 in osteoclast activity in vitro. Journal of Bone and Mineral Metabolism, 2008, 26, 543-550.	1.3	10
63	Patient Healthcare Trajectory and its Impact on the Cost-Effectiveness of Fracture Liaison Services. Journal of Bone and Mineral Research, 2020, 36, 459-468.	3.1	10
64	Advanced practice physiotherapy for adults with spinal pain: a systematic review with meta-analysis. European Spine Journal, 2021, 30, 990-1003.	1.0	9
65	Polymeric Systems as Nanodevices for siRNA Delivery. Current Gene Therapy, 2013, 13, 358-369.	0.9	9
66	Metabolic activity of osteoblasts from periprosthetic trabecular bone in failed total hip arthroplasties and osteoarthritis as markers of osteolysis and loosening. Journal of Rheumatology, 2002, 29, 1437-45.	1.0	9
67	Outcomes assessment in the SPRINT multicenter tibial fracture trial: Adjudication committee size has trivial effect on trial results. Journal of Clinical Epidemiology, 2011, 64, 1023-1033.	2.4	8
68	Rationale, study design, and descriptive data of the Lucky Boneâ,,¢ Fracture Liaison Service. Archives of Osteoporosis, 2019, 14, 19.	1.0	8
69	Chitosan Nanoparticles for Non-Viral Gene Therapy. ACS Symposium Series, 2006, , 177-200.	0.5	7
70	Economic evaluation of advanced practice physiotherapy models of care: a systematic review with meta-analyses. BMC Health Services Research, 2021, 21, 1214.	0.9	7
71	Use of IMMPACT Recommendations to Explore Pain Phenotypes in People with Knee Osteoarthritis. Pain Medicine, 2022, 23, 1708-1716.	0.9	6
72	A novel inÂvitro system for intracellular delivery of nonviral DNA. Journal of Orthopaedic Translation, 2014, 2, 157-164.	1.9	4

#	Article	IF	CITATIONS
73	A lateral approach defect closure technique with deep fascia flap for valgus knee TKA. Journal of Orthopaedic Surgery and Research, 2015, 10, 173.	0.9	4
74	Gene therapy of arthritis and orthopaedic disorders: current experimental approaches in China and in Canada. Expert Opinion on Biological Therapy, 2008, 8, 1337-1346.	1.4	2
75	Finite element analysis of an acetabular trial implant. , 2010, 2010, 3930-3.		1
76	Trajectories of Follow-up Compliance in a Fracture Liaison Service and Their Predictors: A Longitudinal Group-Based Trajectory Analysis. Health Services Research and Managerial Epidemiology, 2021, 8, 233339282110470.	0.5	1
77	Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis' - authors' reply. Arthritis Research and Therapy, 2013, 15, 406.	1.6	O
78	Single session compared with multiple sessions of education and exercise for older adults with spinal pain in an advanced practice physiotherapy model of care: protocol for a randomised controlled trial. BMJ Open, 2021, 11, e053004.	0.8	0